Electronic ArticlesInsulin infusion therapy in critical care patients: Regular insulin vs short-acting insulin. A prospective, crossover, randomized, multicenter blind study☆,☆☆
Introduction
Insulin infusion therapy (IIT) is widely used as “standard of care” to treat hyperglycemia in critical care patients [1], [2]. This therapeutic approach leads to reduced morbidity and to a higher survival rate in some subgroups of critical care patients but is also associated with a substantial risk of inducing hypoglycemia [3], [4], [5]. Various strategies have been used to minimize the risk of iatrogenic-induced hypoglycemia during IIT including wider glycemia target ranges, sliding scale insulin titration, increased frequency of blood glucose concentration (BGC) measurements, and a higher caloric intake [6], [7], [8]. Whether these therapeutic measures do indeed provide greater safety margins remains controversial as does their impact on clinical benefit of IIT [9], [10].
Clinical application of IIT is usually accomplished with regular human insulin (Hlin) (HumulinR; Eli Lilly, Indianapolis, IN) continuous infusion [11], [12]. Shorter acting insulin formulations, such as lispro insulin (Hlog) (Humalog; Eli Lilly) have faster onset and offset kinetics than Hlin and may thus be more suitable for IIT in critical care patients [13], [14], [15]. The molecular structure of Hlog is characterized by a change in the amino acid sequence of the insulin B chain—with proline in position 28 and lysine in position 29 inverted Lys(B28),Pro(B29). This pharmacokinetic profile, which resembles that of endogenous insulin, leads to a faster rise in plasma concentration, a higher peak concentration, and a shorter duration of action than Hlin [12], [13], [16], [17]. The use of Hlog in patients receiving chronic insulin therapy is associated with a faster BGC reduction when infusion is started and a reduced “residual effect” when infusion is stopped [18]. In the critical care setting, a similar effect may be potentially beneficial due to a decreased risk of hypoglycemia in the carryover phase, after insulin infusion is discontinued. However, controlled clinical data on the use of shorter acting insulin formulations in critical care patients are lacking.
We describe the effect of short-acting insulin on blood glucose during continuous infusion and after discontinuation of infusion in critically ill patients, compared with that of regular insulin (the current standard of care).
Section snippets
Materials and methods
This prospective, randomized, crossover, multicenter, clinical trial received institutional review board approval for human research from the University of Rome “La Sapienza,” Italy (approval March 28, 2013, protocol no. 390/13, Chairman: Prof. Aldo Isidori) and from the Valencia University Hospital Institutional Review Board (President Dr Antonio Pelaez) and was registered at the clinicaltrials.gov (NCT 02165566). Written informed consent was obtained from the patients or their next of kin
Patients
A total of 36 patients were randomized to 1 of the 2 treatments. Five patients assigned as first treatment to Hlin and 3 patients assigned to Hlog had no subsequent severe hyperglycemia (BGC > 180 mg/dL) and were, therefore, not assigned to the other treatment (see Fig. 2 for CONSORT diagram). Twenty-eight patients were treated with both Hlog and Hlin. Demographic and clinical data are summarized in Table 1. During the study period, all patients received only parenteral nutrition with a mean
Discussion
In this prospective randomized pilot study performed in critical care patients, the clinical effects of IIT with Hlog or Hlin—during and after insulin infusion—were compared. With Hlog, as compared with Hlin, during insulin infusion, the rate of BGC reduction was faster, and after insulin discontinuation, the extent and duration of carryover effect were more limited and the rate of BGC increase was more rapid. These results suggest that shorter acting insulin analogs such as Hlog have a safer
Conclusions
In conclusion, in ICU patients, the use of short-acting insulin Hlog for IIT at a fixed dose, when compared with Hlin at the same dose, is associated with a less profound carryover effect on BGC after insulin infusion is discontinued. The use of Hlog, when compared with Hlin, is also associated with a higher rate of BGC reduction during insulin infusion—leading to faster attainment of the target BGC range—a shorter duration of carryover and a higher rate of BGC increase after insulin infusion
References (32)
- et al.
Adapting to the new consensus guidelines for managing hyperglycemia during critical illness: the updated Yale insulin infusion protocol
Endocr Pract
(2012) - et al.
Glycemic control in the ICU
Chest
(2011) - et al.
Insulin analogues
Lancet
(1997) - et al.
Glycemia management in neurocritical care patients: a review
J Neurosurg Anesthesiol
(2009) Intensive insulin therapy in critically ill hospitalized patients: making it safe and effective
J Diabetes Sci Technol
(2011)- et al.
Effect of different blood glucose target levels on the incidence of hypoglycemia during insulin therapy in the intensive care unit
J Diabetes
(2013) Reducing hypoglycaemia with insulin analogues
Int J Obes (Lond)
(2002)- et al.
Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients
Crit Care Med
(2012) - et al.
Intensive versus conventional glucose control in critically ill patients
N Engl J Med
(2009) - et al.
Glycemia management in critical care patients
World J Diabetes
(2012)
Glucose management in the neurosurgical patient: are we yet any closer?
Curr Opin Anaesthesiol
Intensive insulin therapy in critically ill patients
N Engl J Med
[Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin
Diabetes
The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences
Diabetes Obes Metab
Short acting insulin analogues in ICU patients
World J Diabetes
Insulin analogues: an example of applied medical science
Diabetes Obes Metab
Cited by (12)
Controversies in Management of Hyperkalemia
2018, Journal of Emergency MedicineCitation Excerpt :Hypoglycemia occurs due to several reasons, chiefly including that insufficient amounts of glucose are available to replace the glucose transported into the hepatic and skeletal muscle cells as a consequence of the insulin infusion. Also, insulin possesses a longer half-life in patients with renal disease (33,75–77). A single bolus of 25 g of dextrose may be insufficient to avoid hyperglycemia at 60 min in renal insufficiency patients, given the longer duration of effect of insulin, which occurs because insulin is eliminated primarily via renal mechanisms.
Treatment of hyperkalemia: Something old, something new
2016, Kidney InternationalCitation Excerpt :If glucose is given as a bolus, hyperglycemia occurs in the first few minutes, which may blunt the kalemic effect of insulin; hyperglycemia leads to water movement from the intracellular to extracellular compartment, favoring potassium efflux from cells through solvent drag.59,60 Hypoglycemia often develops an hour or more after the start of therapy for 2 reasons: (i) the amount of glucose is insufficient to replace the glucose utilized in response to exogenous insulin; (ii) insulin’s prolonged half-life in end-stage renal disease leads to insulin levels high enough to promote glucose utilization for more than an hour.40,61–63 Retrospective studies confirm that hypoglycemia commonly occurs within 1 to 3 hours when hyperkalemia is treated with insulin and indicate that its incidence depends more on the dose of glucose than on the dose of insulin; for example, in one study, 2 of 5 patients given only 5 units of insulin with 25 g of glucose developed a blood glucose <2.2 mmol/l.64
Insulin Other Hypoglycemic Drugs
2016, Side Effects of Drugs AnnualCitation Excerpt :The lowest average blood glucose reached by participants was statistically significantly lower in the regular insulin group as compared to the lispro group (108.7 vs 117.2, respectively, p = 0.003). Blood glucose also increased at a faster rate following discontinuation of infusion in the lispro group as compared to the regular insulin group (p < 0.001) [9c]. 97 pregnant women with either preexisting T2D or gestational diabetes mellitus at ≤ 34 weeks were randomized to receive either long-acting insulin detemir or intermediate-acting NPH for glycemic control in an open-label, noninferiority study.
Stability of 1-unit/mL insulin aspart solution in cyclic olefin copolymer vials and polypropylene syringes
2022, American Journal of Health-System Pharmacy
- ☆
Clinical trial registered with: www.ClinicalTrials.gov (NCT 02165566).
- ☆☆
Disclosure: The authors have no conflicts of interest. No corporate funds have been used to support this study.